Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin
Main finding · Treatment intensificationResult — go to the resultHazard ratio 0.69 95% CI 0.64–0.73Authors' conclusion
Therapeutic inertia still remains a major barrier, with multiple factors associated with delay in intensification. Interventions to overcome therapeutic inertia need to be implemented at both patient and health care professional level.
Study context
- Population
- Adults with T2DM recently started on basal insulin with suboptimal glycaemia (HbA1c within 12 months of basal insulin (BI) ≥ 7% (≥53 mmol/mol)), UK CPRD GOLDanalysed
- Participants
- 12,556 adults
- Exposure
- Patient characteristics associated with time to treatment intensification
- Outcome
- Time to treatment intensification
Methodological detailsmultivariable Cox regression
- Multivariable Cox regression
Main finding
Treatment intensification
Hazard ratio
0.69
95% CI 0.64–0.73
Aged ≥ 65 yearsvs Aged < 65 years
HR 0.69 (95% CI 0.64–0.73)
As reported in the abstract
- Female
- HR 0.93, 0.89-0.99
- Longer T2DM duration
- HR 0.99, 0.98-0.99
- Living in the most deprived areas
- HR 0.90, 0.83-0.98
- Current smoker
- HR 0.91, 0.84-0.98
- One comorbidity
- HR 0.91, 0.85-0.97
- More than one comorbidity
- HR 0.88, 0.82-0.94
- On metformin vs not
- HR 0.71, 0.63-0.80
- On 2nd generation sulphonylureas vs not
- HR 0.85; 0.79-0.92
- On DPP4 inhibitors vs not
- HR 0.87, 0.82-0.93
Observational data: associations, not effects.
Original publication
Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin. Diabetes Res Clin Pract. Published 19 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →